Gallium nitrate for the treatment of non-Hodgkin’s lymphoma

Bibliography

• JEMAL A, MURRAY T, SAMUELS A, GHAFOOR A, WARD E, THUN MJ: Cancer statistics, 2003. CA Cancerj Clin. (2003) 53:5–26.
   PubMed Web of Science ®Google Scholar
• ••Statistics on the incidence of NHL.
   Google Scholar
• HAGEMEISTER FB: Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Cheinother: Pharinacol (2002) 49 (Supp1.1):S13–S20.
   Google Scholar
• MINK SA, ARMITAGE JO: High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist (2001) 6:247–256.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Seinin.Oncol. (2003) 30:434–447.
   PubMed Web of Science ®Google Scholar
• CHESON BD: Radioimmunotherapy ofnon-Hodgkin lymphomas. Blood (2003) 101:391–398.
   PubMed Web of Science ®Google Scholar
• EDWARDS CL, HAYES RL: Tumor scanning with 67Ga citrate. J. Nucl. Med. (1969) 10:103–105.
   PubMed Web of Science ®Google Scholar
• FRONT D, ISRAEL 0: The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin. Nucl. Med. (1995) 25:60–71.
   PubMed Web of Science ®Google Scholar
• VAN AMSTERDAM JA, KLUIN-NELEMANS JC, VAN ECK-SMIT BL, PAUWELS EK: Role of 67Ga scintigraphy in localization of lymphoma. Ann. Hematol. (1996) 72:202–207.
   PubMed Web of Science ®Google Scholar
• HART MM, ADAMSON RH: Antitumoractivity and toxicity of salts of inorganic group Ilia metals: aluminum, gallium, indium and thallium. Proc. Nati Acad. Sci. USA (1971) 68:1623–1626.
   PubMed Web of Science ®Google Scholar
• ADAMSON RH, CANELLOS GP, SIEBER SM: Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group Ilia metal salts. Cancer Cheinother. Rep. (1975) 59:599–610.
   PubMedGoogle Scholar
• NEWMAN RA, BRODY AR, KRAKOFF IH: Gallium nitrate (NSC-15200) induced toxicity in the rat. Cancer (1979) 44: 1728-1740.
   Google Scholar
• FOSTER BJ, CLAGETT-CARR K, HOTH D, LEYLAND-JONES B: Gallium nitrate: the second metal with clinical activity. Cancer Treat. Rep. (1988) 70:1311-1319. Review of gallium nitrate.
   Google Scholar
• WEICK JK, STEPHENS RL, BAKER LH, JONES SE: Gallium nitrate in malignant lymphoma: A Southwest Oncology (Huntingt) Group study. Cancer Treat. Rep. (1983) 67:823–825.
   PubMedGoogle Scholar
• ••Clinical trial using the brief intravenousadministration schedule of gallium nitrate in NHL.
   Google Scholar
• WARRELL RP Jr, COONLEY CJ, STRAUS DJ, YOUNG CW: Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer (1983) 51:1982–1987.
   PubMed Web of Science ®Google Scholar
• ••Pivotal Phase I/II clinical evaluation ofcontinuous intravenous infusion for gallium nitrate. The study demonstrated significant efficacy in relapsed and refractory NHL and Hodgkin's disease and established the standard schedule for the current multi-center national clinical trial of gallium nitrate in NHL.
   Google Scholar
• KELLER J, BARTOLUCCI A, CARPENTER JT Jr, FEAGLERJ: Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial. Cancer TreaiRep. (1986) 70:1221–1223.
   PubMed Web of Science ®Google Scholar
• ••Clinical study of brief infusion gallium nitrate in NHL, Hodgkin's disease and chronic lymphocytic leukaemia.
   Google Scholar
• WARRELL RP Jr, DANIEU L, COONLEY CJ, ATKINS C: Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate and etoposide. Cancer Treat. Rep. (1987) 71:47–51.
   PubMedGoogle Scholar
• ••Clinical study using gallium nitrate incombination with other investigational drugs for the treatment of relapsed NHL. High response rates, including complete remissions, were noted in this study.
   Google Scholar
• CHITAMBAR CR, ZAHIR SA, PITCH PS, ANDERSON T: Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am. .1. Clin. Oncol (1997) 20:173–178.
   PubMed Web of Science ®Google Scholar
• ••Clinical study of the combination ofgallium nitrate and hydroxyurea based on preclinical studies of mechanisms of action. This study confirmed the response rates reported previously by Warren eta]. [14].
   Google Scholar
• EINHORN L: Gallium nitrate in the treatment of bladder cancer. Semin. Oncol (2003) 30:34–41.
   PubMed Web of Science ®Google Scholar
• •Review of gallium nitrate in the treatment of bladder cancer.
   Google Scholar
• BERNSTEIN LR: Mechanisms of therapeutic activity for gallium. Pharmacol Rev (1998) 50:665–682.
   PubMed Web of Science ®Google Scholar
• ••General review of gallium nitrate.
   Google Scholar
• COLLERY P, KEPPLER B, MADOULET C, DESOIZE B: Gallium in cancer treatment. Grit. Rev Oncol Hematol (2002) 42:283–296.
   PubMed Web of Science ®Google Scholar
• ••Review of gallium compounds focusing oncancer therapeutics.
   Google Scholar
• HARRIS WR, PECORARO VL: Thermodynamic binding constants for gallium transferrin. Biochemistry (1983) 22:292–299.
   PubMed Web of Science ®Google Scholar
• VALLABHAJOSULA SR, HARWIG JF, SIEMSEN JK, WOLF W: Radiogallium localization in tumors: blood binding and transport and the role of transferrin. Nucl. Med. (1980) 21:650–656.
   Web of Science ®Google Scholar
• HARRIS AW, SEPHTON RG: Transferrin promotion of 67Ga and 59Fe uptake by cultured mouse myeloma cells. Cancer Res. (1977) 37:3634–3638.
   PubMed Web of Science ®Google Scholar
• RASEY JS, NELSON NJ, LARSON SM:Tumor cell toxicity of stable gallium nitrate: enhancement by transferrin and protection by iron. Eur. j Cancer Clin. Oncol (1982) 18:661–668.
   PubMedGoogle Scholar
• CHITAMBAR CR, SELIGMAN PA: Effects of different transferrin forms on transferrin receptor expression, iron uptake and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium." Clin. Invest. (1986) 78:1538–1546.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, MASSEY EJ, SELIGMAN PA: Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide. Gin. Invest. (1983) 72:1314–1325.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, ZIVKOVIC Z: Uptakeof gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res. (1987) 47:3929–3934.
   PubMed Web of Science ®Google Scholar
• CHAN SM, HOFFER PB, DURAY P: Inhibition of gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody.' Nucl. Med. (1987) 28:1303–1307.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, ZIVKOVIC-GILGENBACH Z: Role of the acidic receptosome in the uptake and retention of 67Ga by human leukemic HL60 cells. Cancer Res. (1990) 50:1484–1487.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, SAX D: Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells. Blood (1992) 80:505–511.
   PubMed Web of Science ®Google Scholar
• KATSIR 0, MALIK Z: Toxic effects of gallium nitrate on Friend erythroleukemia cells. Cancer (1997) 10:43–48.
   Web of Science ®Google Scholar
• KOVARJ, SELIGMAN P, GELFAND EW: Differential growth-inhibitory effects of gallium on B-lymphocyte lines in high versus low iron concentrations. Cancer Res. (1990) 50:5727–5730.
   PubMed Web of Science ®Google Scholar
• SELIGMAN PA, SCHLEICHER RB, SIRIWARDANA G, DOMENICO J, GELFAND EW: Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. Blood (1993) 82:1608–1617.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, MATTHAEUS WG, ANTHOLINE WE, GRAFF K, O'BRIEN WJ: Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood(1988) 72: 1930-1936.
   Google Scholar
• •Mechanism of action: investigation identifying ribonucleotide reductase as a target for the antineoplastic action of gallium.
   Google Scholar
• HEDLEY DW, TRIPP ED, SLOWIACZEK P, MANN GJ: Effect of gallium on DNA synthesis by human T-cell lymphoblasts. Cancer Res. (1988) 48:3014–3018.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, NARASIMHAN J: Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology (1991) 59:3–10.
   PubMed Web of Science ®Google Scholar
• THELANDER L, REICHARD P: Reduction of ribonucleotides. Ann. Rev. Biochem. (1979) 48:133–158.
   PubMed Web of Science ®Google Scholar
• NUTTER LM, CHENG Y-C: Nature and properties of mammalian ribonucleoside diphosphate reductase. In: Inhibitors of Ribonucleoside Diphosphate Reductase Activig". JG Cory, AH Cory (Eds), Pergamon Press, New York, USA (1989)37–54.
   Google Scholar
• PETERSSON L, GRASLUND A, EHRENBERG A, SJOBERG B-M, REICHARD P: The iron center in ribonucleotide reductase from Escherichia coil J. Biol. Chem. (1980) 255:6706–6712.
   Web of Science ®Google Scholar
• GRASLUND A, SAHLIN M, SJOBERG B-M: The tyrosyl free radical in ribonucleotide reductase. Environ. Health Perspect. (1985) 64:139–149.
   PubMed Web of Science ®Google Scholar
• NARASIMHAN J, ANTHOLINE WE, CHITAMBAR CR: Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem. Pharmacol (1992) 44:2403–2408.
   PubMed Web of Science ®Google Scholar
• •Mechanism of action: investigation showing that the R2 subunit of ribonucleotide reductase is a target for the antiproliferative action of gallium.
   Google Scholar
• CHITAMBAR CR, NARASIMHAN J, GUY J, SEM DS, O'BRIEN WJ: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res. (1991) 51:6199–6201.
   PubMed Web of Science ®Google Scholar
• •Mechanism of action: investigation showing that gallium nitrate also inhibits ribonucleotide reductase enzyme activity independent of action on cellular iron homeostasis.
   Google Scholar
• WAALKES TP, SANDERS K, SMITH RG, ADAMSON RH: DNA polymerases of Walker 256 carcinosarcoma. Cancer Res. (1974) 34:385–391.
   PubMed Web of Science ®Google Scholar
• BERGGREN MM, BURNS LA, ABRAHAM RT, POWIS G: Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res. (1993) 53:1862–1866.
   PubMed Web of Science ®Google Scholar
• ANGHILERI LJ, THUVENOT P, BRUNOTTE F, MARCHAL C, ROBERT J: Ionic competition and 67Ga in vivo accumulation. Nuklearmedizin (1982) 21:114–116.
   PubMedGoogle Scholar
• PERCHELLET EM, LADESICH JB, COLLERY P, PERCHELLET JP: Microtubule-disrupting effects of gallium chloride in vitro. Anticancer Drugs (1999) 10:477–488.
   PubMed Web of Science ®Google Scholar
• LUNDBERG JL, CHITAMBAR CR: Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res. (1990) 50:6466–6470.
   PubMed Web of Science ®Google Scholar
• •Preclinical study demonstrating drug synergy between gallium nitrate and fludarabine. This has implications for clinical trial design.
   Google Scholar
• MYETTE MS, ELFORD HL, CHITAMBAR CR: Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase. Cancer Lett. (1998) 129:199–204.
   PubMed Web of Science ®Google Scholar
• •Preclinical study demonstrating drug synergy between gallium nitrate and gemcitabine. This has implications for clinical trial design.
   Google Scholar
• CHITAMBAR CR, WERELEY JP, HAQ RU: Synergistic inhibition of T-lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human a-interferon through action on cellular iron uptake. Cancer Res. (1994) 54:3224–3228.
   PubMed Web of Science ®Google Scholar
• •Preclinical study demonstrating drug synergy between gallium nitrate and IFN-a. This has implications for clinical trial design.
   Google Scholar
• HATA Y, SANDLER A, LOEHRER PJ, SLEDGE GW Jr, WEBER G: Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res. (1994) 6:19–24.
   PubMed Web of Science ®Google Scholar
• •Preclinical study demonstrating drug synergy between gallium nitrate and paclitaxel. This has implications for clinical trial design.
   Google Scholar
• WARRELL RP Jr, ALCOCK NW, BOCKMAN RS: Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases.' Clin. Oncol (1987) 5:292–298.
   Web of Science ®Google Scholar
• WARRELL RP Jr, LOVETT D, DILMANIAN FA, SCHNEIDER R, HEELAN RT: Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study.' Clin. Oncol (1993) 11:2443–2450.
   Web of Science ®Google Scholar
• BOCKMAN R: The effects of gallium nitrate on bone resorption. Semin.Oncol (2003) 30:5–12.
   PubMed Web of Science ®Google Scholar
• •Review of gallium nitrate in bone metabolism.
   Google Scholar
• WARRELL RP Jr: Clinical trials of gallium nitrate in patients with cancer-related hypercalcemia. Semin.Oncol (1991) 18:26–31.
   PubMedGoogle Scholar
• •Review of gallium nitrate for the treatment of hypercalcaemia.
   Google Scholar
• TODD PA, FITTON A: Gallium nitrate: a review of its pharmacological properties and therapeutic potential in cancer-related hypercalcemia. Drugs (1991) 42:261–273.
   PubMed Web of Science ®Google Scholar
• •Review of gallium nitrate for the treatment of hypercalcaemia.
   Google Scholar
• MATKOVIC V, BALBOA A, CLINCHOT D et al: Gallium prevents adjuvant arthritis in rats and interferes with macrophage/T-cell function in the immune response. Carr. Ther. Res. (1991) 50:255–267.
   Web of Science ®Google Scholar
• DROBYSKI WR, HAQ RU, MAJEWSKI D, CHITAMBAR CR: Modulation of in vitro and in vivoT-cell responses by transferrin-gallium and gallium nitrate. Blood (1996) 88:3056–3064.
   PubMed Web of Science ®Google Scholar
• OROSZ CG, WAKELY E, BERGESE SDet al.: Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody. Transplantation (1996) 61:783–791.
   Google Scholar
• WHITACRE C, APSELOFF G, COX K, MATKOVIC V, JEWELL S, GERBER N: Suppression of experimental autoimmune encephalomyelitis by gallium nitrate. Neuroimmunol (1992) 39:175–181.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, SEIGNEURET MC, MATTHAEUS WG, LUM LG: Modulation of lymphocyte proliferation and immunoglobulin production by transferrin-gallium. Cancer Res. (1989) 49:1125–1129.
   PubMed Web of Science ®Google Scholar
• MAKKONEN N, H1RVONEN M-R, SAVOLAINEN K, LAPINJOKI S, MONKKONEN J: The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro. Inflamm. Res. (1995) 44:523–528.
   PubMed Web of Science ®Google Scholar
• PELOSI E, TESTA U, LOUACHE F et al:Expression of transferrin receptors in phytohemagglutinin-stimulated human T-lymphocytes. Biol. Chem. (1986) 261:3036–3042.
   Web of Science ®Google Scholar
• FUTRAN J, KEMP JD, FIELD EH, VORA A, ASHMAN RF:Transferrin receptor synthesis is an early event in B cell activation. Immunol (1989) 143:787–792.
   Web of Science ®Google Scholar
• KELSEN DP, ALCOCK N, YEH S, BROWN J, YOUNG C: Pharmacokinetics of gallium nitrate in man. Cancer (1980) 46:2009–2013.
   PubMed Web of Science ®Google Scholar
• KRAKOFF IH, NEWMAN RA, GOLDBERG RS: Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer (1979) 44:1722–1727.
   PubMed Web of Science ®Google Scholar
• SAMSON MK, FRAILE RJ, BAKER LH, O'BRYAN R: Phase I-II clinical trial of gallium nitrate (NSC-15200). Cancer Gin. Trials (1980) 3:131–136.
   PubMedGoogle Scholar
• BEDIKIAN AY, VALDIVIESO M, BODEY GP et al.: Phase I clinical studies with gallium nitrate. Cancer Treat. Rep. (1978) 62:1449–1453.
   PubMedGoogle Scholar
• HABESHAW JA, LISTER TA, STANSFELD AG: Correlation of transferrin receptor expression with histological class and outcome in Non-Hodgkin lymphoma. Lancet (1983) 1:498–501.
   PubMed Web of Science ®Google Scholar
• •Demonstration of transferrin receptor expression on lymphoma cells in biopsies taken from patients. This has implications for the targeting of transferrin-gallium complexes to the transferrin receptor in NHL.
   Google Scholar
• ESSERMAN L, TAKAHASHI S, ROJAS V, WARKNE R, LEVY R: An epitope of the transferrin receptor is exposed on the cell surface of high-grade lymphoma but not low-grade human lymphomas. Blood (1989) 74:2718–2729.
   PubMed Web of Science ®Google Scholar
• RADICE PA, BUNN PAJ, IHDE DC: Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas and other malignancies. Cancer Treat.Rep. (1979) 63:1231–1239.
   PubMedGoogle Scholar
• CARTER SK: Adriamycin - a review. Natl. Cancer Inst. (1975) 55:1265–1274.
   Google Scholar
• CAVALLI F, JUNGI WE NISSEN NI, PAJAK TF, COLEMAN M, HOLLAND JF: Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of 540 the cancer and acute leukemia group B. Cancer (1981) 48: 1927-1930.
   Google Scholar
• RODRIGUEZ V, McCREDIE KB, VALDIVIESO M, BODEY GP, FREIREICH EJ: Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat. Rep. (1978) 62:439–497.
   PubMedGoogle Scholar
• KANTARJIAN H, BARLOGIE B, PLUNKETT W et al.: High-dose cytosine arabinoside in non-Hodgkin's lymphoma. Clin. Oncol (1983) 1:689–694.
   Web of Science ®Google Scholar
• REDMAN JR, CABANILLAS F, VELASQUEZ WS et al: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. Clin. Oncol (1992) 10:790–794.
   Web of Science ®Google Scholar
• O'BRIEN ME, MATUTES E, CUNNINGHAM D et al.: Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leak. Lymphoma (1994) 14:17–23.
   PubMed Web of Science ®Google Scholar
• SAVEN A, PIRO LD: 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann. Int. Med. (1994) 120:784–791.
   PubMed Web of Science ®Google Scholar
• HOFFMAN M, TALLMAN MS, HAKIMIAN D et al.: 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. I Clin. Omni (1994) 12:788–792.
   Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• CHITAMBAR CR, ZIVKOVIC-GILGENBACH Z, NARASIMHAN J, ANTHOLINE WE: Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. Cancer Res. (1990) 50:4468–4472.
   PubMed Web of Science ®Google Scholar